strong rais po continu
across board rais po
report adj ep estimate/consensu better
expect revenu margin patient care cost lower
expect third straight quarter despit open nine clinic
meanwhil provid initi guidanc rang bracket expect
well receiv overal achiev high end guidanc rang
despit volatil year expect rate stabil beyond
increas ep estim tax reform roll estim
rais po ebitda-nci vs previous reiter
buy rate guidanc appear conserv see upsid cost save
establish adj ebitda-nci guidanc y/i
outlook bracket expect prior estimate/consensu
midpoint expect effect tax rate y/i tax reform final
expect spend revenu develop capital-expenditure
mainten capital-expenditure line expect note clinic pipelin remain
strong vs previous overal think guidanc well receiv
see upsid oper initi drug cost save look color
commerci outlook today earn call
margin better despit open nine clinic quarter
net revenu declin y/i estim better
expect volum price treatment increas y/i organ
acquir estim non-acquir growth slow tough
comp remain strong revenu per treatment y/i
better estim although appear impact one-tim item
ebitda margin y/i better
estim lower expect patient care cost oper initi
appear track despit open nine clinic one neg
minor interest came vs expect
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
nation provid dialysi servic
compani oper dialysi clinic serv
patient chronic kidney failur also known
differenti model oper
physician partnership model partner
nephrologist develop oper dialysi
dialysi stabl recur busi
defens area health care facil
addit compani jv model help
recruit nephrologist facilit open
de novo clinic strong econom
high margin consist
shown abil take market share
consist grow top line doubl digit
po base ebitda-nci estim view uniqu
growth strong ebitda margin warrant premium multipl
growth end-stag renal diseas esrd lack altern result
above-averag demand dialysi next sever year
downsid risk manag care repres vast major profit
dialysi provid declin number insur rate pressur commerci
contract could pressur margin addit medicar rate lacklust
could regulatori scrutini compani jv structur time
kevin fischbeck cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us facil hospit manag healthcar coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
